AddLife acquires Irish company O’Flynn Medical and German company BioCat.
O’Flynn Medical is an independent distributor offering product sales, rental and technical services to the hospital sector, private customers and nursing homes in Ireland. The company will become part of the Healthcare 21 Group, which AddLife acquired to the business area Medtech in 2021. O’Flynn Medical is an Irish company with annual net sales of approximately EUR 6.4 million and 36 employees.
O’Flynn Medical is a great strategic fit for Healthcare 21, with a strong market position, it provides interesting opportunities to expand Healthcare 21’s portfolio into the rental market segment and become the leading provider in Ireland. The acquisition also provides an entry for Healthcare 21 into the bariatric market segment, states AddLife.
“The acquisition of O’Flynn Medical means that we are strengthening our presence in the Irish and UK market where we already have major expertise and market presence. O’Flynn Medical will form a bolt-on acquisition to Healthcare 21 to complement existing product portfolios whilst also entering into new market segments”, says Kristina Willgård, CEO AddLife AB
AddLife is also continuing its expansion in Europe by acquiring BioCat, for inclusion in its Labtech business area. BioCat is a specialized distributor of products and services to the life science research market with annual revenues of EUR 9 million. The company is located in Germany but also has sales in Austria and Switzerland, giving AddLife the opportunity for further expansion in these markets.
BioCat offers a wide portfolio of instruments and research reagents within the fast-growing fields of genomics, proteomics and cell biology to academia as well as to the pharma and biotech industry. The company distributes products and services from approximately 70 suppliers. The acquisition strengthens AddLife’s presence in Germany and opens up opportunities for cooperation with our other companies in Europe that are active in the same product segment, it states.
BioCat is located in Heidelberg. The business has its own sales force but also sales through a web shop. The majority of the 20 employees work within sales and support.
”The acquisition of BioCat is a first step for Business area Labtech into the German market in an interesting segment where we already have major expertise and market presence in several other European countries,” says Kristina Willgård, CEO of AddLife AB.
Photo of Kristina Willgård: AddLife